Henan Lingrui Pharmaceutical Co Ltd (600285.SS)
23 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Henan Lingrui Pharmaceutical to acquire 33.33 pct stake in biological pharmaceutical firm for 66.7 mln yuan
- BRIEF-Henan Lingrui Pharmaceutical to buy back up to 300 mln yuan worth of company shares
- BRIEF-Henan Lingrui Pharmaceutical To Invest 100 Million Yuan In Investment Fund
- BRIEF-Henan Lingrui Pharmaceutical To Buy Back 300 Million Yuan Worth Of Company Shares
- BRIEF-Henan Lingrui Pharmaceutical passes review of high-tech enterprise recognition